Context Therapeutics Inc (CNTX)

[Hercules1]

$CNTX:


this is hitting $3 today.

[TheFinalCD]

CNTX HALTED UP^^^

[Welsh_Dragon]

What a gift in the AM .90-1.25

[reena969]

Lol

[TheFinalCD]

ugh hope the breakfast was really good

but how much did it cost ya

[TheFinalCD]

CNTX craking now, you jump in

[TheFinalCD]

wow that one is still going

@m@zing

[reena969]

Yes I have two of them..lol.... both healthy, no lumps

[reena969]

maybe it was the .09...No more eating and Trading...Just looked at the canceled order it was .09 not .90 OMG

[reena969]

I didn't get fill @.09...this is fucking Ridiculous NOT ONE SHARE!!!!

[TheFinalCD]

NICE I BOUGHT .92Z

[tortiello]

FDA APPROVAL AGAINST BREAST CANCER, $$$$$$$$$

[reena969]

I'm calling a dip buy @ market open on CNTX , since I was late ...Hope that's better, eating breakfast Syrup on my keys....lol

[reena969]

nice 7.84 exit after a hold over night. That I started not to hold. almost 200% Then I got logged off with a claim someone else had logged onto my account....BULLSHIT...

[reena969]

I think I'm going to have to fire a broker. I was mysteriously logged off After I executed the trade
Hmmm
That's why it's good to have more than 3. They can't stop a girl from Banking.

[tortiello]

ME Also $$$$$$$$$$$$$$

[reena969]

just finished MSGM now I'm here $$$$$

[TheFinalCD]

https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-clinical-partner-stemline-therapeutics

[tw0122]

Let’s go

[Awl416]

News

[Tom turtles]

Yes...locked and loaded myself. way undervalued

[cary73]

Doubled my position yesterday now we stand by

[Tom turtles]

Today was better ...74s going down Waiting for $1.50

[cary73]

I'm waiting ... I hope you'll be happy soon

[Tom turtles]

Very soon....collect those cheapies

[Tom turtles]

70s Holding

[Tom turtles]

Holding 70s

[cary73]

continues to fall I do not see interest in the title ... wait but this continuous descent .....

[cary73]

I'm waiting

[Tom turtles]

Give it time. Loading zone. Our day will come

[cary73]

Good morning,
I can't understand how it can be so undervalued, looking at the case and the pipeline...

[Tom turtles]

Love this price !

[Tom turtles]

Oh.... people are ...Huge buying opp

[DH112]

Surprised people aren't jumping on this opp

[DH112]

HUGE PR NEW THIS MORNING 730

[DH112]

Buying this HUGE DIP

[MonopolyTrader]

Check this. $43m cash on hand and good until almost 2024 $CNTX

$CNTX $43,000,000 cash on hand and will be sufficient to fund operations into 4th quarter 2023! With clinical trials finishing up and more starting before end of year. pic.twitter.com/ek2JhetPlp

— Ugly American Capital (@UglyAmericanx) August 12, 2022

[TheFinalCD]

$CNTX We have the whole rest of the week to run it up. Nice float, Cash, and great catalysts coming up. https://t.co/AKsZId31J8

— Zack Morris (@MrZackMorris) May 31, 2022

[golfndude]

$10 price target initiated today and it’s $2.28 ? Let’s go

[10stars]

Got some at these low prices! Ready for next week!

IB borrow fee data:
Fee, Available, Updated
111.7 %, 100,000, 2021-12-31 11:45:03

[10stars]

CNTX could run hard with some good news, IB borrow Fee = 103.4 % as of 2021-12-29 16:45:03

[BoilerRoom]

$CNTX $3.11

[stock1ace1]

5.74$

[crudeoil24]

Long ways to go > Context Therapeutics Inc. (NASDAQ:CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS).

The Phase 0 open-label, single-arm, multicenter ONAWA (SOLTI-1802) trial conducted by Spanish cancer research group SOLTI, enrolled 10 patients with ER+/PR+/HER2- negative tumors and levels of the cell proliferation marker "Ki67" above 10% to evaluate ONA-XR by the rate of Complete Cell Cycle Arrest (CCCR) determined by Ki-67 (≤2.7%) when administered for three weeks prior to surgery (Abstract #511). Secondary endpoints of the trial included safety and correlating biological activity with immunohistochemistry (IHC) of tumor expression (ER, PR, Ser294-PgR, CD24, CD44, ALDH1, Ki-67), estradiol, and progesterone blood levels, and gene expression profile (NanoString nCounter® Breast 360TM panel). While no patients achieved a CCCR, tumor Ki-67 expression decreased in six patients, remained stable in one patient, and increased in three patients. Mean percentage decrease of Ki67 for tumors with baseline PR expression ≥90% (N=4) and <90% (N=6) was -25.23% and 2.54%, respectively, indicating a trend towards enhance response for patients with high levels of PR expression at baseline. In addition, a shift towards more endocrine-sensitive disease was detected, implying an increased chance of the tumor responding to anti-estrogen therapy when used in combination with ONA-XR. Six patients reported adverse events (AEs), of which most were grade 1 or 2 including post-procedural pain, dry mouth, and an increase of gamma-glutamyl transferase (GGT). One patient experienced Grade 3 reversible GGT and aspartate aminotransferase (AST).

"The data from the ONAWA trial signal the potential of ONA-XR to help inhibit tumor proliferation and shift tumors to a more endocrine treatment-sensitive phenotype during treatment prior to surgery in postmenopausal women with operable breast cancer and improve overall prognosis for these patients," said co-principal investigator Meritxell Bellet, M.D., Ph.D., medical oncologist at Vall d'Hebron University Hospital in Barcelona and an executive board member of SOLTI. "These results support further evaluation of ONA-XR in the treatment of early breast cancer."

"ONA-XR is being evaluated in four investigator-sponsored clinical trials in hormone-driven breast, ovarian and endometrial cancers. This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers," said Martin Lehr, CEO of Context Therapeutics. "We look forward to data updates from three other ONA-XR trials in 2022."

The design of two additional clinical trials evaluating ONA-XR in metastatic breast cancer (MBC) were also presented in trials-in-progress posters during SABCS: The SMILE Study, a Phase 2 trial evaluating ONA-XR in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors that is being conducted in collaboration with the Wisconsin Oncology Network (Abstract #311); and Memorial Sloan Kettering Cancer Center's Phase 1b trial designed to define the safety, tolerability and recommended Phase 2 dose of ONA-XR in combination with letrozole and palbociclib, in addition to investigating the circulating tumor DNA-guided response of this triplet therapy regimen in high-risk patients (Abstract #1538).

[reena969]

Looks interesting $9.84 post market, If it dips at 7am I'm in for the ride to $10-$12 https://finance.yahoo.com/news/context-therapeutics-announces-positive-data-230000057.html

[sony12]

Any thoughts here

[PinkPennies]

CNTX nice news just out https://finance.yahoo.com/news/context-therapeutics-announces-positive-data-230000057.html

[Surfacetite]

looks like today. https://seekingalpha.com/pr/18570770-context-therapeutics-to-present-clinical-data-on-ona-xr-in-breast-cancer-2021-san-antonio

[Marvy]

When is data due?

[Clippy]

I think you're right :)